Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of “Buy” from Analysts

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have received an average recommendation of “Buy” from the six analysts that are currently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued a report on the stock in the last year is $39.00.

AKRO has been the topic of a number of research analyst reports. HC Wainwright lifted their target price on Akero Therapeutics from $40.00 to $43.00 and gave the stock a “buy” rating in a report on Friday, March 1st. UBS Group lifted their target price on Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th.

Insider Buying and Selling

In related news, insider Catriona Yale sold 20,646 shares of Akero Therapeutics stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $35.49, for a total value of $732,726.54. Following the transaction, the insider now owns 78,415 shares of the company’s stock, valued at approximately $2,782,948.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Akero Therapeutics news, COO Jonathan Young sold 5,000 shares of Akero Therapeutics stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $24.38, for a total transaction of $121,900.00. Following the transaction, the chief operating officer now owns 263,306 shares of the company’s stock, valued at approximately $6,419,400.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Catriona Yale sold 20,646 shares of Akero Therapeutics stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $35.49, for a total value of $732,726.54. Following the transaction, the insider now directly owns 78,415 shares in the company, valued at approximately $2,782,948.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 100,646 shares of company stock valued at $3,319,877. 9.69% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bourgeon Capital Management LLC purchased a new position in Akero Therapeutics during the 1st quarter valued at about $383,000. Quattro Financial Advisors LLC grew its stake in Akero Therapeutics by 43,378.3% during the 1st quarter. Quattro Financial Advisors LLC now owns 10,000 shares of the company’s stock valued at $253,000 after acquiring an additional 9,977 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in Akero Therapeutics during the 1st quarter valued at about $211,000. Vanguard Group Inc. grew its stake in Akero Therapeutics by 2.4% during the 4th quarter. Vanguard Group Inc. now owns 3,085,048 shares of the company’s stock valued at $72,036,000 after acquiring an additional 72,866 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Akero Therapeutics by 247.7% during the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock valued at $67,294,000 after acquiring an additional 2,053,028 shares in the last quarter.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO opened at $20.76 on Friday. Akero Therapeutics has a fifty-two week low of $11.25 and a fifty-two week high of $58.38. The firm’s 50-day simple moving average is $24.77 and its 200 day simple moving average is $21.73. The company has a quick ratio of 29.27, a current ratio of 29.27 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.44 billion, a P/E ratio of -7.28 and a beta of -0.38.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.17). Equities analysts expect that Akero Therapeutics will post -4.06 EPS for the current year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.